natgillin/translations-raw huggingface dataset:
Odefsey bør ikke administreres sammen med andre lægemidler, der indeholder tenofoviralafenamid, lamivudin, tenofovirdisoproxil eller adefovirdipivoxil (se pkt. 
Odefsey should not be co-administered with other medicinal products containing tenofovir alafenamide, lamivudine, tenofovir disoproxil or adefovir dipivoxil (see section 4.5).
Odefsey bør generelt undgås, men kan anvendes med forsigtighed hos voksne med nyresygdom i slutstadiet (estimeret CrCl < 15 ml/min) i kronisk hæmodialyse, hvis de potentielle fordele opvejer de potentielle risici (se pkt. 
Odefsey should generally be avoided but may be used with caution in adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis if the potential benefits outweigh the potential risks (see section 4.2).
Mens De tager Odefsey 
While you are taking Odefsey
Dyrestudier indikerer ikke direkte eller indirekte skadelige virkninger med hensyn til reproduktionstoksicitet (se pkt. 
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3) with the components of Odefsey.
Indlægsseddel: Information til brugeren Odefsey 200 mg/25 mg/25 mg filmovertrukne tabletter emtricitabin/rilpivirin/tenofoviralafenamid Dette lægemiddel er underlagt supplerende overvågning. 
Package leaflet: Information for the user Odefsey 200 mg/25 mg/25 mg film-coated tablets emtricitabine/rilpivirine/tenofovir alafenamide This medicine is subject to additional monitoring.
Croscarmellosenatrium Lactose (som monohydrat) Magnesiumstearat Mikrokrystallinsk cellulose Polysorbat 20 
Croscarmellose sodium Lactose (as monohydrate) Magnesium stearate Microcrystalline cellulose Polysorbate 20
Administration af Odefsey sammen med lægemidler, der hæmmer CYP3A-enzymaktivitet, er blevet observeret at øge plasmakoncentrationerne af rilpivirin. 
Co-administration of Odefsey with medicinal products that inhibit CYP3A enzyme activity has been observed to increase rilpivirine plasma concentrations.
Nedsat nyrefunktion Dosisjustering af Odefsey er ikke nødvendig hos voksne og unge (i alderen mindst 12 år og med en legemsvægt på mindst 35 kg) med en estimeret kreatininclearance (CrCl) ≥ 30 ml/min. 
No dose adjustment of Odefsey is required in adults or in adolescents (aged at least 12 years and of at least 35 kg body weight) with estimated creatinine clearance (CrCl) ≥ 30 mL/min.
Odefsey er ikke blevet undersøgt hos patienter med svært nedsat leverfunktion (Child-Pugh klasse C); derfor frarådes det at bruge Odefsey hos patienter med svært nedsat leverfunktion (se pkt. 
Odefsey has not been studied in patients with severe hepatic impairment (Child Pugh Class C); therefore, Odefsey is not recommended for use in patients with severe hepatic impairment (see sections 4.4 and 5.2).
Når der korrigeres for proteinbinding, er plasmakoncentrationer af ubundet (frit) tenofoviralafenamid sammenlignelige ved svært nedsat leverfunktion og normal leverfunktion. 
When corrected for protein binding, unbound (free) plasma concentrations of tenofovir alafenamide in severe hepatic impairment and normal hepatic function are similar.
De må ikke amme, mens De er i behandling med Odefsey. 
Do not breast-feed during treatment with Odefsey.
Den mediane alder var 36 år, 78 % var mænd, 62 % var hvide og 24 % sorte/afroamerikanere. 
The median age was 36 years, 78% were male and 62% White and 24% Black/African American.
Farmakokinetik, sikkerhed, tolerabilitet og virkning af en dosis en gang dagligt på 25 mg rilpivirin, i kombination med et investigatorvalgt BR med to NRTI'er, blev evalueret i studiet TMC278-C213, et åbent fase 2-studie med en enkelt arm af antiretroviral-naive hiv 1-inficerede pædiatriske patienter i alderen 12 til < 18 år, som vejede mindst 32 kg. 
The pharmacokinetics, safety, tolerability, and efficacy of rilpivirine 25 mg once daily, in combination with an investigator-selected BR containing two NRTIs, were evaluated in Study TMC278-C213, a single-arm, open-label Phase 2 study in antiretroviral-naïve HIV-1 infected paediatric patients 12 to < 18 years of age and weighing at least 32 kg.
Den gennemsnitlige stigning i forhold til baseline i CD4+-celletal var 230 celler/mm3 hos patienter behandlet med E/C/F/TAF og 211 celler/mm3 hos patienter behandlet med E/C/F/TDF (p = 0,024) ved uge 48 og 326 celler/mm3 hos patienter behandlet med E/C/F/TAF og 305 celler/mm3 hos patienter behandlet med E/C/F/TDF (p = 0,06) ved uge 144. 
The mean increase from baseline in CD4+ cell count was 230 cells/mm3 in E/C/F/TAF-treated patients and 211 cells/mm3 in E/C/F/TDF-treated patients (p = 0.024) at Week 48 and 326 cells/mm3 in E/C/F/TAF-treated patients and 305 cells/mm3 in E/C/F/TDF-treated patients (p = 0.06) at Week 144.
• et lavt antal blodplader (en type blodlegemer, der er med til at få blodet til at størkne) 
• low platelet count (a type of blood cell involved in clotting blood)
• Hvis De for tiden tager nogen af følgende lægemidler: carbamazepin, oxcarbazepin, phenobarbital og phenytoin (anvendes til at behandle epilepsi og forebygge krampeanfald) rifabutin, rifampicin og rifapentin (anvendes til at behandle visse bakterieinfektioner som f.eks. tuberkulose) 
• If you are currently taking any of the following medicines: - carbamazepine, oxcarbazepine, phenobarbital and phenytoin (used to treat epilepsy and prevent seizures) - rifabutin, rifampicin and rifapentine (used to treat some bacterial infections such as tuberculosis)
Tenofoviralafenamid er aktiv mod hepatitis B (HBV). 
Tenofovir alafenamide is active against hepatitis B virus (HBV).
d Omfatter patienter, som havde ≥ 50 kopier/ml i uge 48- eller uge 144-vinduet, patienter, som afbrød behandlingen tidligt som følge af manglende eller svigtende virkning, patienter, som afbrød behandlingen af andre årsager end en bivirkning (AE), død eller manglende eller svigtende virkning, og som på tidspunktet for seponering havde en virusbelastning på ≥ 50 kopier/ml. 
d Includes patients who had ≥ 50 copies/mL in the Week 48 or Week 144 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Der blev ikke rapporteret nogen anormale laboratorieværdier af grad 3-4 for ASAT/ALAT eller bivirkninger af grad 3-4 med forhøjet transaminase (se pkt. 
No Grade 3-4 laboratory abnormalities for AST/ALT or Grade 3-4 adverse reactions of transaminase increased were reported (see section 5.1).
Odefsey indeholder lactosemonohydrat. 
Odefsey contains lactose monohydrate.
Hos patienter, som samtidig var inficerede med hepatitis B- eller C-virus, der fik rilpivirin, var forekomsten af forhøjet leverenzym højere end hos patienter uden samtidig infektion, der fik rilpivirin. 
In patients co-infected with hepatitis B or C virus receiving rilpivirine, the incidence of hepatic enzyme elevation was higher than in patients receiving rilpivirine who were not co-infected.
Ældre Dosisjustering af Odefsey er ikke nødvendig hos ældre patienter (se pkt. 
Elderly No dose adjustment of Odefsey is required in elderly patients (see section 5.2).
NARKOTISKE ANALGETIKA Metadon (60-100 mg en gang dagligt, individualiseret dosis)/ rilpivirin 
NARCOTIC ANALGESICS Methadone (60-100 mg once daily, individualised dose)/ Rilpivirine
Eksponeringer for emtricitabin og tenofoviralafenamid givet sammen med elvitegravir + cobicistat, som blev opnået for 24 pædiatriske patienter i alderen 12 til < 18 år, svarede til eksponeringer, som blev opnået hos behandlingsnaive voksne patienter (tabel 6). 
Exposures of emtricitabine and tenofovir alafenamide given with elvitegravir + cobicistat achieved in 24 paediatric patients aged 12 to < 18 years were similar to exposures achieved in treatment-naïve adults (Table 6).
Tenofoviralafenamid absorberes hurtigt efter oral administration med maksimale plasmakoncentrationer 15-45 timer efter dosering. 
Tenofovir alafenamide is rapidly absorbed following oral administration, with peak plasma concentrations occurring at 15-45 minutes post-dose.
De hyppigst rapporterede bivirkninger i kliniske studier hos behandlingsnaive patienter, som fik emtricitabin + tenofoviralafenamid i kombination med elvitegravir + cobicistat, var kvalme (11 %), diarré (7 %) og hovedpine (6 %). 
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat were nausea (11%), diarrhoea (7%), and headache (6%).
3 Bivirkninger identificeret i kliniske studier af lægemidler indeholdende emtricitabin + tenofoviralafenamid. 
3 Adverse reactions identified from clinical studies of emtricitabine + tenofovir alafenamide-containing products.
Vurderingen af bivirkninger er baseret på sikkerhedsdata fra alle fase 2- og 3-studier, hvor 2.396 patienter fik emtricitabin + tenofoviralafenamid sammen med elvitegravir + cobicistat som en fastdosis-kombinationstablet, samlede data fra 686 patienter, der fik rilpivirin 25 mg én gang daglig i kombination med andre antiretrovirale lægemidler i de kontrollerede studier TMC278-C209 og TMC278-C215, 754 patienter, der fik Odefsey i studierne GS-US-366-1216 og GS-US-366-1160, samt erfaringer efter markedsføring. 
Assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies in which 2,396 patients received emtricitabine + tenofovir alafenamide given with elvitegravir + cobicistat as a fixed-dose combination tablet, pooled data from 686 patients who received rilpivirine 25 mg once daily in combination with other antiretroviral medicinal products in the controlled studies TMC278-C209 and TMC278-C215, 754 patients who received Odefsey in Studies GS-US-366-1216 and GS-US-366-1160, and post-marketing experience.
Hvis De tager en H2-antagonist, som f.eks. famotidin, cimetidin, nizatidin eller ranitidin, skal De tage den mindst 12 timer før eller mindst 4 timer efter Odefsey. 
If you are taking an H2-antagonist such as famotidine, cimetidine, nizatidine or ranitidine, take it at least 12 hours before or at least 4 hours after Odefsey.
En patient med nyopstået resistens (M184M/I) blev identificeret i et klinisk studie af virologisk supprimerede patienter, der skiftede fra et regime indeholdende emtricitabin + tenofovirdisoproxilfumarat til E/C/F/TAF i en fastdosis kombinationstablet (GS-US-292-0109, n = 959). 
One patient with emergent resistance (M184M/I) was identified in a clinical study of virologically suppressed patients who switched from a regimen containing emtricitabine + tenofovir disoproxil fumarate to E/C/F/TAF in a fixed-dose combination (FDC) tablet (GS-US-292-0109, n = 959).
Intracellulært tenofovir fosforyleres dernæst til den aktive metabolit tenofovirdiphosphat. 
Intracellular tenofovir is subsequently phosphorylated to the active metabolite tenofovir diphosphate.
• Antimykotika, der anvendes til at behandle svampeinfektioner: 
• Antifungal medicines used to treat fungal infections:
• føle sig oppustet 
• feeling bloated
Efter virusbelastning ved baseline (kopier/ml) 
By baseline viral load (copies/mL)
I studier med behandlingsnaive patienter, der fik emtricitabin + tenofoviralafenamid (FTC + TAF) eller emtricitabin + tenofovirdisoproxilfumarat (FTC + TDF), begge givet sammen med elvitegravir + cobocistat som en fastdosis-kombinationstablet, blev der i begge behandlingsgrupper observeret stigninger i forhold til baseline i faste-lipidparametrene total-kolesterol, direkte lavdensitets-lipoprotein (LDL)- og højdensitets-lipoprotein (HDL)-kolesterol og triglycerider ved uge 144. 
In studies in treatment-naïve patients receiving emtricitabine + tenofovir alafenamide (FTC + TAF) or emtricitabine + tenofovir disoproxil fumarate (FTC + TDF), both given with elvitegravir + cobicistat as a fixed-dose combination tablet, increases from baseline were observed in both treatment groups for the fasting lipid parameters total cholesterol, direct low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol, and triglycerides at Week 144.
Hvis De tager et syreneutraliserende middel, som f.eks. aluminiums-/magnesiumhydroxid eller calciumcarbonat, skal De tage det mindst 2 timer før eller mindst 4 timer efter Odefsey. 
If you are taking an antacid such as aluminium/magnesium hydroxide, or calcium carbonate, take it at least 2 hours before or at least 4 hours after Odefsey.
• besvær med at falde i søvn 
• difficulty sleeping (insomnia)
2 Studiet blev udført med emtricitabin/rilpivirin/tenofovirdisoproxilfumarat fastdosis-kombinationstablet. 
2 Study conducted with emtricitabine/rilpivirine/tenofovir disoproxil fumarate fixed-dose combination tablet.
Hvis patienten glemmer at tage en dosis Odefsey, men kommer i tanker om det inden for 12 timer efter tidspunktet, hvor patienten normalt tager dosen, skal patienten tage Odefsey sammen med mad så snart som muligt og derefter fortsætte med den normale doseringsplan. 
If the patient misses a dose of Odefsey within 12 hours of the time it is usually taken, the patient should take Odefsey with food as soon as possible and resume the normal dosing schedule.
f Omfatter patienter, som afbrød behandlingen af andre årsager end en AE, død eller manglende eller svigtende virkning, f.eks. tilbagetrækning af samtykke, tabt for opfølgning osv. 
f Includes patients who discontinued for reasons other than an AE, death, or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.
HDPE-beholder (højdensitets-polyethylen) med børnesikret skruelåg af polypropylen foret med induktionsaktiveret aluminiumsfolie indeholdende 30 filmovertrukne tabletter. 
High density polyethylene (HDPE) bottle with a polypropylene continuous-thread, child-resistant cap, lined with an induction activated aluminium foil liner containing 30 film-coated tablets.
Tabel 2: Bivirkninger i tabelform 
Table 2: Tabulated list of adverse reactions
I studier med Odefsey hos virologisk supprimerede voksne patienter blev der i uge 96 efter skift til Odefsey set stigning i BMD for hofte sammenlignet med minimale ændringer ved fortsat behandling med FTC/RPV/TDF eller EFV/FTC/TDF (middelændring 1,6 % for Odefsey versus -0,6 % for FTC/RPV/TDF, p < 0,001; 1,8 % for Odefsey versus -0,6 % for EFV/FTC/TDF, p < 0,001) og for ryg (middelændring 2,0 % for Odefsey versus -0,3 % for FTC/RPV/TDF, p < 0,001; 1,7 % for Odefsey versus 0,1 % for EFV/FTC/TDF, p < 0,001). 
In Odefsey studies in virologically suppressed adult patients, increases in BMD were noted at 96 weeks after switching to Odefsey compared to minimal changes with maintaining FTC/RPV/TDF or EFV/FTC/TDF at the hip (mean change 1.6% for Odefsey versus -0.6% for FTC/RPV/TDF, p < 0.001; 1.8% for Odefsey versus -0.6% for EFV/FTC/TDF, p < 0.001) and the spine (mean change 2.0% for Odefsey versus -0.3% for FTC/RPV/TDF, p < 0.001; 1.7% for Odefsey versus 0.1% for EFV/FTC/TDF, p < 0.001).
syreneutraliserende midler (aluminium-/magnesiumhydroxid eller calciumcarbonat) 
antacids (aluminium/magnesium hydroxide or calcium carbonate)
Aktive stoffer: emtricitabin, rilpivirin og tenofoviralafenamid. 
The active substances are emtricitabine, rilpivirine and tenofovir alafenamide.
Lægemidler, der aldrig må tages sammen med Odefsey: - carbamazepin, oxcarbazepin, phenobarbital og phenytoin (anvendes til at behandle epilepsi og forebygge krampeanfald) - rifabutin, rifampicin og rifapentin (anvendes til at behandle visse bakterieinfektioner som f.eks. tuberkulose) 
Medicines that must never be taken with Odefsey: carbamazepine, oxcarbazepine, phenobarbital and phenytoin (used to treat epilepsy and prevent seizures) rifabutin, rifampicin and rifapentine (used to treat some bacterial infections such as tuberculosis)
Hæmning af P-gp 
Inhibition of P-gp
Vurderingen af rilpivirins sikkerhed er baseret på data fra uge 48 fra ét åbent studie med en enkelt arm (TMC278-C213) af 36 pædiatriske patienter i alderen 12 til < 18 år, som alle vejede mindst 32 kg. Ingen patienter afbrød behandlingen med rilpivirin på grund af bivirkninger. 
The safety assessment of rilpivirine is based on Week 48 data from one single-arm open-label study (TMC278-C213) in 36 paediatric patients 12 to < 18 years and weighing at least 32 kg. No patients discontinued rilpivirine due to adverse reactions.
4 Bivirkning identificeret i sikkerhedsovervågningen efter markedsføring af emtricitabin/rilpivirin/tenofovirdisoproxilfumarat. 
4 Adverse reaction identified through post-marketing surveillance of emtricitabine/rilpivirine/tenofovir disoproxil fumarate.
Patienter med kronisk hepatitis B eller C, som er i antiretroviral behandling, har en øget risiko for svære og potentielt letale, hepatiske bivirkninger. 
Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Behandlingsnaive hiv 1-inficerede voksne patienter Virkningen af rilpivirin er baseret på analyser af 96 ugers data fra to randomiserede, dobbeltblindede, kontrollerede studier af behandlingsnaive patienter (TMC278-C209 og undersættet med emtricitabin + tenofovirdisoproxilfumarat fra TMC278-C215). 
Treatment-naïve HIV-1 infected adult patients The efficacy of rilpivirine is based on the analyses of 96 weeks data from two randomised, double-blind, controlled studies in treatment-naïve patients (TMC278-C209 and emtricitabine + tenofovir disoproxil fumarate subset of TMC278-C215).
Tabel 4: Virologiske resultater af randomiseret behandling i studierne TMC278-C209 og TMC278-C215 (samlede data for patienter, der fik rilpivirinhydrochlorid eller efavirenz i kombination med FTC/TDF) ved uge 48 (primært) og uge 96 
Table 4: Virologic outcomes of randomised treatment of Studies TMC278-C209 and TMC278-C215 (pooled data for patients receiving rilpivirine hydrochloride or efavirenz in combination with FTC/TDF) at Week 48 (primary) and Week 96
Emtricitabin er en nukleosid-revers transkriptasehæmmer (NRTI, nucleoside reverse transcriptase inhibitor) og analog til 2'-deoxycytidin. 
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and analogue of 2'-deoxycytidine.
I den samlede analyse for TMC278-C209 og TMC278-C215 af 1096 patienter, som fik et baggrundsregime (BR) med FTC/TDF, var demografiske karakteristika og karakteristika ved baseline afbalanceret mellem grupperne med rilpivirin og efavirenz (EFV). 
In the pooled analysis for TMC278-C209 and TMC278-C215 of 1,096 patients who received a background regimen (BR) of FTC/TDF, demographic and baseline characteristics were balanced between the rilpivirine and efavirenz (EFV) arms.
Emtricitabin har aktivitet mod hiv 1, hiv 2 og HBV. 
Emtricitabine has activity against HIV-1, HIV-2, and HBV.
Der er utilstrækkelige data (færre end 300 gravide forsøgspersoner) fra anvendelse af rilpivirin og tenofoviralafenamid til gravide kvinder (se pkt. 
There are a limited amount of data (less than 300 pregnancy outcomes) from the use of rilpivirine and tenofovir alafenamide in pregnant women (see sections 4.4, 5.1 and 5.2).
Antimykobakterielle lægemidler Rifampicin/rilpivirin 
Antimycobacterials Rifampicin/ Rilpivirine
Den kliniske virkning af Odefsey blev klarlagt i studier udført med emtricitabin + tenofoviralafenamid, givet sammen med elvitegravir + cobicistat som en E/C/F/TAFfastdosis-kombinationstablet, i studier med rilpivirin, givet sammen med FTC/TDF som individuelle komponenter eller som en FTC/RPV/TDF-fastdosis-kombinationstablet, og i studier med Odefsey. 
Clinical efficacy of Odefsey was established from studies conducted with emtricitabine + tenofovir alafenamide when given with elvitegravir + cobicistat as an E/C/F/TAF FDC tablet, from studies conducted with rilpivirine when given with FTC/TDF as individual components or as a FTC/RPV/TDF FDC tablet, and from studies conducted with Odefsey.
ORALE ANTIKONCEPTIVA Ethinylestradiol (0,035 mg en gang dagligt)/rilpivirin 
ORAL CONTRACEPTIVES Ethinylestradiol (0.035 mg once daily)/ Rilpivirine
Cmin: I/R 
Cmin: N/A
Der forventes signifikante fald i plasmakoncentrationer af rilpivirin (reduceret absorption, stigning i gastrisk pH). 
Significant decreases in rilpivirine plasma concentrations are expected (reduced absorption, increase in gastric pH).
Rilpivirins farmakokinetik hos antiretroviral-naive hiv 1-inficerede pædiatriske patienter i alderen 12 til < 18 år, som fik 25 mg rilpivirin en gang dagligt, kunne sammenlignes med den for behandlingsnaive hiv 1-inficerede voksne, som fik 25 mg rilpivirin en gang dagligt. 
The pharmacokinetics of rilpivirine in antiretroviral-naïve HIV-1 infected paediatric patients 12 to < 18 years of age receiving rilpivirine 25 mg once daily was comparable to that in treatment-naïve HIV-1 infected adults receiving rilpivirine 25 mg once daily.
I studierne GS-US-292-0104 og GS-US-292-0111 udviste E/C/F/TAF statistisk superioritet i forhold til E/C/F/TDF i at opnå hiv 1-rna < 50 kopier/ml ved uge 144. 
In Studies GS-US-292-0104 and GS-US-292-0111, E/C/F/TAF demonstrated statistical superiority in achieving HIV-1 RNA < 50 copies/mL when compared to E/C/F/TDF at Week 144.
clarithromycin erythromycin Disse lægemidler kan øge mængden af rilpivirin og tenofoviralafenamid (indholdsstoffer i Odefsey) i Deres blod. 
clarithromycin erythromycin These medicines can increase the amount of rilpivirine and tenofovir alafenamide (components of Odefsey) in your blood.
De hyppigst observerede aminosyresubstitutioner, som opstod, omfattede: L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C og M230I. 
The most commonly observed amino acid substitutions that emerged included: L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C, and M230I.
Når De snart ikke har mere af Odefsey, skal De bede om mere fra lægen eller på apoteket. 
When your supply of Odefsey starts to run low, get more from your doctor or pharmacist.
Disse lægemidler kan øge mængden af rilpivirin og tenofoviralafenamid (indholdsstoffer i Odefsey) i Deres blod. 
These medicines can increase the amount of rilpivirine and tenofovir alafenamide (components of Odefsey) in your blood.
HYPNOTIKA/SEDATIVA Midazolam (2,5 mg enkelt dosis oralt)/tenofoviralafenamid 
HYPNOTICS/SEDATIVES Midazolam (2.5 mg, orally, single dose)/ Tenofovir alafenamide
• dexamethason (orale og parenterale doser), undtagen som enkeltdosisbehandling • perikon (Hypericum perforatum). 
• dexamethasone (oral and parenteral doses), except as a single dose treatment
Samlet respons og en undergruppeanalyse af virologisk respons (< 50 hiv 1-rna-kopier/ml) ved både 48 uger og 96 uger samt virologisk svigt efter virusbelastning ved baseline (samlede data fra de to kliniske fase 3-studier, TMC278-C209 og TMC278-C215, for patienter, der fik BR FTC/TDF) præsenteres i tabel 4. 
Overall response and a subgroup analysis of the virologic response (< 50 HIV-1 RNA copies/mL) at both 48 weeks and 96 weeks, and virologic failure by baseline viral load (pooled data from the two Phase 3 clinical studies, TMC278-C209 and TMC278-C215, for patients receiving the FTC/TDF BR) are presented in Table 4.
ANTIDIABETIKA Metformin (850 mg enkeltdosis)/ rilpivirin 
ANTIDIABETICS Metformin (850 mg single dose)/ Rilpivirine
Odefsey kan påvirke eller blive påvirket af anden medicin. 
Odefsey may interact with other medicines.
Rilpivirin viste også antiviral aktivitet mod et bredt panel af primære isolater af hiv 1 gruppe M (undertype A, B, C, D, F, G, H), med EC50-værdier i intervallet fra 0,07 til 1,01 nM (0,03 til 0,37 ng/ml), primære isolater af gruppe O med EC50-værdier i intervallet fra 2,88 til 8,45 nM (1,06 til 3,10 ng/ml), og det viste begrænset aktivitet in vitro mod hiv 2 med EC50-værdier i intervallet fra 2.510 til 10.830 nM (920 til 3.970 ng/ml). 
Rilpivirine also demonstrated antiviral activity against a broad panel of HIV-1 group M (subtype A, B, C, D, F, G, H) primary isolates with EC50 values ranging from 0.07 to 1.01 nM (0.03 to 0.37 ng/mL), group O primary isolates with EC50 values ranging from 2.88 to 8.45 nM (1.06 to 3.10 ng/mL), and showed limited in vitro activity against HIV-2 with EC50 values ranging from 2,510 to 10,830 nM (920 to 3,970 ng/mL).